1010 related articles for article (PubMed ID: 12206800)
1. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
[TBL] [Abstract][Full Text] [Related]
2. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients.
Aartsma-Rus A; Janson AA; Kaman WE; Bremmer-Bout M; den Dunnen JT; Baas F; van Ommen GJ; van Deutekom JC
Hum Mol Genet; 2003 Apr; 12(8):907-14. PubMed ID: 12668614
[TBL] [Abstract][Full Text] [Related]
4. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
6. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
8. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
van Deutekom JC; Bremmer-Bout M; Janson AA; Ginjaar IB; Baas F; den Dunnen JT; van Ommen GJ
Hum Mol Genet; 2001 Jul; 10(15):1547-54. PubMed ID: 11468272
[TBL] [Abstract][Full Text] [Related]
9. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
10. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
12. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
13. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
14. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
[TBL] [Abstract][Full Text] [Related]
15. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.
Mann CJ; Honeyman K; Cheng AJ; Ly T; Lloyd F; Fletcher S; Morgan JE; Partridge TA; Wilton SD
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):42-7. PubMed ID: 11120883
[TBL] [Abstract][Full Text] [Related]
16. Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.
Yokota T; Pistilli E; Duddy W; Nagaraju K
Expert Opin Biol Ther; 2007 Jun; 7(6):831-42. PubMed ID: 17555369
[TBL] [Abstract][Full Text] [Related]
17. Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?
Yokota T; Duddy W; Echigoya Y; Kolski H
Expert Opin Biol Ther; 2012 Sep; 12(9):1141-52. PubMed ID: 22650324
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides, exon skipping and the dystrophin gene transcript.
Wilton SD; Fletcher S
Acta Myol; 2005 Dec; 24(3):222-9. PubMed ID: 16629057
[TBL] [Abstract][Full Text] [Related]
19. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.
Aartsma-Rus A; Janson AA; Kaman WE; Bremmer-Bout M; van Ommen GJ; den Dunnen JT; van Deutekom JC
Am J Hum Genet; 2004 Jan; 74(1):83-92. PubMed ID: 14681829
[TBL] [Abstract][Full Text] [Related]
20. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.
Wilton SD; Fletcher S
Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
